Protein kinase C inhibitors: a patent review (2008 – 2009)
- 29 May 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 23 (10) , 1297-1315
Abstract
Introduction: The protein kinase C (PKC) is a family of multifunctional isoenzymes involved in apoptosis, migration, adhesion, tumorgenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation. It also plays a vital role in the regulation of signal transduction, cell proliferation and differentiation through positive and negative regulation of the cell cycle. In this work, we reviewed the existing PKC inhibitors and several patents linked to PKC inhibitors. Areas covered: Thorough survey on the PKC inhibitors having clinical importance and patents filed for these inhibitors from 2008 – 2009 is reported. Expert opinion: PKCs are highly potential therapeutic targets for treating diabetic complications, oncological, inflammatory, immunological and dermatological disorders. The clinical trial candidates of PKCs mainly target the catalytic domain, which is highly conserved throughout the PKC family making it difficult to target a particular isoform selectively. Relatively less chemical space and fewer bisubstrate inhibitors targeting both ATP and regulatory domain are explored for PKCs, more research in these areas will be helpful in overcoming existing problems.Keywords
This publication has 53 references indexed in Scilit:
- A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancerBreast Cancer Research and Treatment, 2012
- 6-Hydroxydopamine upregulates iron regulatory protein 1 by activating certain protein kinase C isoforms in the dopaminergic MES23.5 cell lineThe International Journal of Biochemistry & Cell Biology, 2012
- Staurosporine Induces Necroptotic Cell Death under Caspase-Compromised Conditions in U937 CellsPLOS ONE, 2012
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesCancer Chemotherapy and Pharmacology, 2010
- Enzastaurin (LY317615), a Protein Kinase C Beta Selective Inhibitor, Enhances Antiangiogenic Effect of RadiationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Phase II Study of Paclitaxel Plus the Protein Kinase C Inhibitor Bryostatin-1 in Advanced Pancreatic CarcinomaAmerican Journal of Clinical Oncology, 2010
- Selectivity and therapeutic inhibition of kinases: to be or not to be?Nature Immunology, 2009
- Butein, a Specific Protein Tyrosine Kinase InhibitorBiochemical and Biophysical Research Communications, 1998
- Rottlerin, a Novel Protein Kinase InhibitorBiochemical and Biophysical Research Communications, 1994
- The protein kinase inhibitor staurosporine, like phorbol esters, induces the association of protein kinase C with membranesBiochemical and Biophysical Research Communications, 1988